Disc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. decreased its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 36.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 350,000 shares of the company's stock after selling 200,000 shares during the period. Adage Capital Partners GP L.L.C. owned 1.18% of Disc Medicine worth $22,190,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in IRON. Tower Research Capital LLC TRC increased its stake in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after acquiring an additional 266 shares during the last quarter. Teacher Retirement System of Texas raised its stake in Disc Medicine by 8.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock valued at $308,000 after purchasing an additional 396 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after acquiring an additional 503 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Disc Medicine by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock worth $400,000 after acquiring an additional 593 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in shares of Disc Medicine by 6.6% in the 4th quarter. MetLife Investment Management LLC now owns 12,132 shares of the company's stock valued at $769,000 after purchasing an additional 755 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

Disc Medicine Stock Performance

NASDAQ:IRON traded down $0.24 during trading hours on Friday, reaching $49.44. The company's stock had a trading volume of 77,101 shares, compared to its average volume of 343,794. The company has a market capitalization of $1.71 billion, a P/E ratio of -12.42 and a beta of 0.77. The stock has a 50 day moving average price of $48.04 and a two-hundred day moving average price of $55.04. Disc Medicine, Inc. has a 12 month low of $28.25 and a 12 month high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.08. As a group, analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 5,574 shares of Disc Medicine stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $304,228.92. Following the completion of the sale, the chief executive officer now owns 154,828 shares of the company's stock, valued at approximately $8,450,512.24. The trade was a 3.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rahul Khara sold 7,500 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $55.54, for a total transaction of $416,550.00. Following the completion of the sale, the insider now directly owns 14,035 shares in the company, valued at $779,503.90. This trade represents a 34.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 361,690 shares of company stock worth $19,648,094 over the last three months. Corporate insiders own 4.24% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IRON. Scotiabank raised their price target on Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $118.00 price target on shares of Disc Medicine in a report on Tuesday, January 21st. Cantor Fitzgerald boosted their target price on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. TD Cowen assumed coverage on Disc Medicine in a research report on Thursday, February 27th. They issued a "buy" rating on the stock. Finally, Morgan Stanley reiterated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Disc Medicine presently has an average rating of "Buy" and an average target price of $93.80.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.